Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2022-01-07 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
关于全资子公司肠癌检测产品获得沙特阿拉伯食品药品管理局批准上市的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen BGI Genomics Co., Ltd. regarding the approval of a colorectal cancer detection product by the Saudi Food & Drug Authority (SFDA). It details the product information, market context, and potential impact on the company. There are no financial statements, regulatory certifications, or detailed financial data present. The document is a formal announcement about a product approval and market expansion, not a financial report or regulatory filing. It is also relatively short (1655 characters) and does not indicate it is a report or presentation. Therefore, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2022-01-07 Chinese
关于回购股份进展暨首次回购公司股份的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Shenzhen BGI Genomics Co., Ltd. regarding the progress of its share repurchase program and the details of its first share buyback. It includes specific information about the number of shares repurchased, prices, compliance with regulatory rules, and references to previous announcements and plans. The document is relatively short (1916 characters) and focuses on the company's share repurchase activity rather than a full financial report or earnings release. This matches the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback of its own shares.
2022-01-06 Chinese
中信证券股份有限公司关于深圳华大基因股份有限公司2021年持续督导现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2021年持续督导现场检查报告" which translates to "2021 Continuous Supervision On-site Inspection Report" by CITIC Securities for Shenzhen BGI Genomics Co., Ltd. It details the on-site inspection of company governance, internal controls, information disclosure, protection of company interests, use of raised funds, performance, and fulfillment of commitments. The document includes detailed findings and compliance checks but does not contain full financial statements or comprehensive annual or interim financial data. It is a standalone audit or inspection report related to regulatory supervision and internal controls rather than a full annual or quarterly report. The document length is 4538 characters, which is substantive and contains detailed inspection content, not merely an announcement or certification. Therefore, it fits best under the category of Audit Report / Information (AR). FY 2021
2022-01-05 Chinese
关于实际控制人兼董事长增持公司股份计划时间过半的进展公告
Director's Dealing Classification · 95% confidence The document is an announcement regarding the progress of a shareholding increase plan by the company's actual controller and chairman. It details the number of shares purchased, the timing, and the amount spent, but it does not contain financial statements or performance data. The document is focused on the insider's share purchase activity and the progress of that plan, which aligns with reporting on transactions by company directors or executives. Therefore, it fits the category of Director's Dealing (DIRS). The document length is 2344 characters, which is typical for such announcements and not a full financial report or earnings release.
2021-12-28 Chinese
中信证券股份有限公司关于深圳华大基因股份有限公司以债转股方式对深圳市早知道科技有限公司增资并受让其部分股权暨关联交易的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from CITIC Securities regarding a specific transaction involving Shenzhen BGI Genomics Co., Ltd. and Shenzhen Early Know Technology Co., Ltd. It discusses a debt-to-equity swap investment and related party transactions, including board meeting approvals, shareholder structures before and after the transaction, financial data of the target company, and detailed information about related parties and investors. The document includes audited financial data, transaction details, and compliance with stock exchange rules. It is not a brief announcement, a voting result, or a certification letter. It is a comprehensive disclosure about a capital investment transaction and related party dealings, which fits the category of Capital/Financing Update (CAP).
2021-12-22 Chinese
关于实际控制人兼董事长增持公司股份计划的进展公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the progress of a share increase plan by the company's actual controller and chairman. It details the number of shares purchased, the dates, prices, and the percentage of total shares held before and after the transactions. There is no financial report, earnings data, or management discussion. The document focuses on the insider's transactions in the company's shares, which fits the definition of a Director's Dealing report.
2021-12-22 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.